News Release

ECRI Finds Significant Gaps in Ease of Use for At-Home COVID Tests

As the consumer demand for COVID-19 rapid tests increased due to the spread of the omicron variant, the nation’s largest non-profit patient safety organization evaluated seven COVID-19 rapid tests and found serious gaps in their usability. According to experts at ECRI, none of the tests were rated as excellent and some had noteworthy usability concerns.

ECRI analyzed seven popular COVID-19 rapid tests based on the well-established System Usability Scale (SUS), which rates products on a scale of 0 to 100 with 100 being the easiest to use. More than 30 points separated the top and bottom tests analyzed.

“Our evaluation shows that some rapid tests are much easier to use than others,” says Marcus Schabacker, MD, PhD, president and CEO of ECRI. “If given options, consumers should choose tests that are the easiest to use because when a test is difficult for a consumer to use, it may lead to an inaccurate result.”

The tests evaluated and their ratings on the SUS scale are:

  1. On/Go                Very Good (82.9)

  2. CareStart            Very Good (80.8)

  3. Flowflex              Very Good (79.5)

  4. QuickVue            Good (75.6)

  5. BinaxNOW          Good (73.3)

  6. InteliSwab          Good (73.3)

  7. BD Veritor          Okay (51.8)

ECRI analysts said some tests require particularly fine motor control or have instructions with extremely small font size that may make it difficult for older adults and others with complex health conditions to use the tests correctly. Often, these groups are more susceptible to contracting COVID-19 and face more severe complications.

Given demand and supply issues, Schabacker said consumers may not be able to choose their rapid test and may have to rely on whatever is available to them. In that case, they should be aware of the specific usability concerns for that test so that they can try to mitigate any factors that may lead to an inaccurate result.

More information about the evaluation of each test can be found at www.ecri.org. For further questions, contact ECRI at [email protected] or 610-825-6000.

More News

The Institute for Safe Medication Practices (ISMP) has identified possible error risks with Paxlovid, which recently received Emergency Use Authorization (EUA) for the treatment of mild-to-moderate COVID-19. An ISMP special alert has been issued to raise awareness and recommend ways to prevent